Skip to main content

Show 54 results Show all

Resources: A list of references about subcutaneous DMPA

This brief lists key references and resources from the evidence base on DMPA-SC. Pair this with the Evidence at-a-glance brief if your target decision-maker would like to have access to the data in that handout.

Institutional author(s): PATH
Publication date: October, 2019

Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

This press release announces the price reduction of Sayana Press from $1 to $0.85 per dose in qualifying countries.

Institutional author(s): Pfizer, Inc.
Publication date: May, 2017

Brief Collaboration helps broaden access to Pfizer’s contraceptive, Sayana® Press (medroxyprogesterone acetate)

Selected practice recommendations for contraceptive use

Along with the World Health Organization (WHO) Medical eligibility criteria for contraceptive use, this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This document provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. Safety considerations include common barriers to safe, correct and consistent use of contraception and the benefits of preventing unintended or unwanted pregnancy.

Institutional author(s): World Health Organization (WHO)
Publication date: 2016

Guide Web page

Medical eligibility criteria for contraceptive use

Along with the World Health Organization (WHO) Selected practice recommendations for contraceptive use this is one of two evidence-based guidance documents of the WHO’s initiative to develop and implement family planning guidelines for national programs. This publication provides guidance to national family planning and reproductive health programs in the preparation of guidelines for the delivery of contraceptive services. The guide provides information on the safety and use of intramuscular and subcutaneous DMPA.

Institutional author(s): World Health Organization (WHO)
Publication date: 2015

Costs and cost-effectiveness of DMPA-SC through different delivery channels: What the evidence tells us

This DMPA-SC Advocacy Pack brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

Institutional author(s): PATH, Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, JSI
Publication date: 2023

Expanded Product Registration Toolkit

The Product Registration Toolkit helps guide the process of registering health products, like contraceptives, in low- and middle-income countries. The toolkit is a digital collection of adaptable, downloadable resources including:

  • A primer on the basics of product registration
  • A regulatory pathway decision tree
  • Checklists for various stages of the registration process
  • Tools to evaluate and track your registration application
  • Templates of commonly required documents
  • Quick reference glossary

All toolkit resources are available in English and French, with the Product Registration Basics guide in English, French, Portuguese, and Spanish.

Institutional author(s): Expanding Effective Contraceptive Options
Publication date: 2023

Contraceptive Innovation Index

To facilitate decision-making around the introduction and scale-up of contraceptive technologies, the Expanding Effective Contraceptive Options (EECO) project, led by WCG Cares in partnership with PSI, and USAID’s Center for Innovation and Impact teamed up to create the Contraceptive Innovation Index. On January 25, 2023, EECO and USAID hosted a webinar on the development and use of this tool; the webinar slides and recording are linked below.

Institutional author(s): Expanding Effective Contraceptive Options, USAID, Population Services International (PSI), WCG Cares
Publication date: 2023

Toward resilient SRH procurement and financing

A new analysis of challenges and opportunities

Shaping Equitable Market Access for Reproductive Health (SEMA Reproductive Health) hosted a September 29 webinar to shed light on Dalberg Advisors’ analysis of the challenges low and middle-income countries face in procuring sexual and reproductive health (SRH) goods. Panelists shared their experiences overcoming challenges to sustainable SRH markets in their respective countries. The webinar recording, Q&A, and resources are available online.

Institutional author(s): Shaping Equitable Market Access for Reproductive Health (SEMA Reproductive Health)
Publication date: September, 2022

Webinar recording

Results 4 Informed Choice

Results 4 Informed Choice is a resource for HIV and family planning program implementers, government representatives, advocates and journalists as they respond to the results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.

The trial results, released June 13, 2019, showed that none of the three contraceptive methods in the trial increased the risk of HIV acquisition. Other findings, including high HIV incidence across the study arms and broad acceptability and effectiveness of the contraceptive methods, are a call to action for greater attention to and investment in women’s health, HIV prevention and contraceptive choice. Full findings from the study can be found in the Lancet article.

The tools, resources and data are intended to help stakeholders plan and execute their response so that women have all the information they need to make an informed choice in adopting and using a contraceptive method and protecting themselves from HIV.

Institutional author(s): Johns Hopkins Center for Communication Programs (JHU CCP)
Publication date: 2022

Tool Link to Website

Burkina Faso: In-depth analysis of family planning task sharing and self-care policies, and alignment with WHO guidelines

This report presents an in-depth analysis of Burkina Faso’s policies, regulations, and guidelines, based on an extensive document review followed by key informant interviews. The findings are organized by select family planning methods, including voluntary surgical contraception, implants, injectables, and pills. The report also includes a section describing COVID-19’s effect on task sharing and self-care policies. The authors recommend policy and regulatory revisions and actions to further improve the country’s family planning and regulatory environment and scale implementation of the World Health Organization (WHO) guidelines and note that the Burkina Faso experience may serve as evidence when the WHO next updates its task sharing guidance.

Institutional author(s): USAID, Human Resources for Health in 2030 (HRH2030)
Publication date: August, 2021